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Osteosarcoma is the most frequent malignant primary bone tumor characterized by a high potency to form lung metastases which
is the main cause of death. Unfortunately, the conventional chemotherapy is not fully eﬀective on osteosarcoma metastases. The
progression of a primary tumor to metastasis requires multiple processes, which are neovascularization, proliferation, invasion,
survival in the bloodstream, apoptosis resistance, arrest at a distant organ, and outgrowth in secondary sites. Consequently,
recent studies have revealed new insights into the molecular mechanisms of metastasis development. The understanding of the
mechanism of molecular alterations can provide the identification of novel therapeutic targets and/or prognostic markers for
osteosarcoma treatment to improve the clinical outcome.
1. Introduction
Osteosarcoma (OS)most often occurs, during childhood and
adolescence, in the metaphysis of long bones, including large
growth plates with high proliferation activity and bone turn-
over [1]. Historically, patients with primary OS have been
treated with resection surgery alone, resulting in poor prog-
nosis. Clinical outcome of localized OS has improved with
neoadjuvant chemotherapies, based on methotrexate, cis-
platin, doxorubicin, and ifosfamide treatments. The 5-year
survival has indeed increased to around 60%. However, the
5-year survival of patients with OS metastasis still remains
about 30% [2–7]. OS metastases appear most frequently in
the lung [8] and are the main cause of death for patients
with OS, because micrometastases are undetectable at initial
diagnosis [9, 10]. Taken together, OS patients withmetastases
present further worse clinical results than those without
metastases. Thus, more eﬀective treatments and/or a more
personalized therapy (i.e., treatments according to specific
genes or protein profile expressions) are needed for patients
with OS associated with pulmonary metastases.
The establishment of cancer metastasis involves several
complex steps: intravasation, survival in the circulation,
arrest at a distant organ, extravasation, and growth in sec-
ondary sites (Figure 1). Molecular alterations of these steps
have been practically analyzed. The understanding of metas-
tasis mechanismmight allow us to find newmolecular targets
for improvement of the patients’ survival. This paper de-
scribes the molecular factors associated with OS devel-
opment and summarizes the main molecular alterations
involved in this bone disease, especially in metastatic OS,
which strongly contribute to the development of novel ther-
apeutic approaches.
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Figure 1: The main steps of the tumor metastatic process. Tumor cells proliferate at the primary site and neovascularization is induced by
tumor environment such as hypoxia. In turn, they migrate and invade into the bloodstream. These tumor cells in the circulation need to
survive against anoikis to arrest in a distant organ. Metastatic colonization at the secondary site involves the interactions between tumor cells
and the microenvironment.
2. Neovascularization is a Key
Parameter in Osteosarcoma Growth
Nutriments and oxygen required for the metabolism of
normal and tumor cells are delivered by blood vessels. Neo-
formation of blood vessels allows growth, invasion, and me-
tastatic spread of cancer cells in malignant pathologies. [11,
12]. The process of neovascularization is generally regulated
by a balance between angiogenic inducers and inhibitors. The
shift in favor of angiogenic inducers, known as the “angiog-
enic switch,” promotes the formation of a new blood supply
enhancing tumor growth and metastasis. Neovascularization
is induced by the tumor environment such as hypoxia, acido-
sis, or inflammation in an oncologic context. In these condi-
tions, both tumor cells and host endothelial cells can increase
the expression of proangiogenic: vascular endothelial growth
factor (VEGF), platelet-derived growth factor (PDGF), basic
fibroblast growth factor (bFGF), and transforming growth
factor (TGF-β) [13–17]. Tumor cells also secrete proteo-
lytic enzymes such as matrix metalloproteinases (MMPs),
which degrade basement membrane and extracellular matrix
(ECM) promoting cell dissemination [18, 19]. MMP-9 is
indeed highly related to the angiogenic switch because it can
activate proangiogenic factors [20, 21]. Several studies have
demonstrated that VEGF or TGF-β expression is associated
with an increase of tumor vascularity, invasion, and poor
prognosis in OS [22–24]. It has been shown that high serum-
VEGF levels in OS correlate with tumor progression, metas-
tasis, and poor prognosis [25, 26]. However, the relationship
between an increase of tumor vascularity and a poor progno-
sis is controversial in OS [27–29].
The well-known angiogenic inhibitors are angiostatin
and endostatin. Angiostatin is a cleavage product of plas-
minogen [30], whereas endostatin is the carboxyl-terminal
fragment of collagen XVIII [31]. They inhibit endothelial
cell proliferation and migration [32]. The resulting antian-
giogenic activity has been demonstrated in various tumor
models in vivo [33–38]. Based on these (pre)clinical results,
clinical trials are currently running to evaluate the eﬀect of
human recombinant endostatin. Although showed a well tol-
erability and safety in patients with malignant solid tumors,
it induces aminor antitumor eﬀect not related to the vascular
changes [39–41]. Inhibition of neovascularization should
suppress tumor growth despite tumor cell heterogeneity
because blood supply is necessary for all tumors to survive.
Furthermore, the available data from animal models and
phase I and II clinical trials of angiostatin and endostatin
have shown that these agents are well-tolerated at therapeutic
doses: 15–600mg/m2/day added to those patients, although
the use of antiangiogenic therapy has raised the debate about
interference with normal physiological processes such as
wound healing and tissue repair [31, 39–43].
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3. Migration and Invasion:
Two Potential Therapeutic Targets
Tumor migration and invasion through the ECM are critical
in metastatic dissemination [15, 16]. Degradation of the
ECM, which leads to migration, invasion, and metastasis,
releases MMPs (MMP-2 and MMP-9, in particular) and m-
calpain in OS [44–46]. In addition, the Wnt/β-catenin, Src-
kinase and Notch signaling pathways are also involved in
migration and invasion [47–55].
MMPs are a family of zinc endopeptidases consisting of
at least 20 diﬀerent members and regulate diﬀerent cellular
metabolic processes [56, 57]. They induce a variety of bio-
logical eﬀects including growth, morphogenesis, apoptosis,
tissue destruction, and cancer formation [58, 59]. Recently,
bisphosphonates have been shown to downregulate MMPs
expression and reduce the invasive potency of OS cells [60–
64]. Disulfiram is also able to control the invasion and me-
tastasis in human OS cells through the MMP-2 and MMP-9
inhibition [65]. Both of m-calpain expression and MMP-2
secretion are inhibited by a siRNA targeting m-calpain in
SAOS-2 cells [46]. m-calpain is also essential in the invasion
and human OS metastasis [46]. These agents related to
proteases represent new therapeutic targets and approaches
to decrease the OS migration and invasion.
Wnt signaling pathway coordinates osteoblast prolifera-
tion and diﬀerentiation [66]. Disruptions in various compo-
nents of the Wnt pathway result in disordered bone develop-
ment and homeostasis [67]. The β-catenin-dependent Wnt
signaling pathway is regulated by secreted Wnt antagonists
divided into two groups. Wnt inhibitory factor 1 (WIF-1)
and the secreted frizzled-related protein family directly bind
to Wnt ligands while the Dickkopf families and sclerostin
are blocking Wnt receptors trough the endocytosis of low-
density lipoprotein receptor-related protein 5/6 coreceptors
[68–71]. This Wnt binding leads to the activation of di-
sheveled, which in turn, releases β-catenin from the axin-
adenomatous polyposis coli-glycogen synthase kinase-3β
complex, causing stabilization and accumulation of β-cate-
nin in the cytoplasm. After its translocation to the nucleus,
β-catenin binds to the T-cell factor/lymphocyte enhancer
factor family of transcription factors and promotes down-
stream target oncogenes such as c-myc, cyclin D, survivin,
and MMPs. These mechanisms are involved in proliferation,
invasion, and metastasis in various human cancers [72–
75]. OS frequently expresses high levels of cytoplasmic
and/or nuclear β-catenin [76], which is also associated with
metastasis [77, 78]. These findings suggest that aberrant Wnt
activation is crucial in multiple cancers, including OS [79–
81]. A preclinical study has demonstrated that the inhibition
of Wnt/β-catenin pathway induced lower levels of nuclear
β-catenin, resulting in downregulation of the β-catenin-
targeted genes such as MMP-9, cyclin-D, c-myc, and survivin
[82]. Several reports have demonstrated thatWIF-1 silencing
due to hypermethylation results in Wnt signaling activation
in a variety of cancer. WIF-1 can inhibit the cell growth
of those cancer cells [79, 80, 83–86]. The downregulation
of WIF-1 expression plays a role in OS progression. Reex-
pression of WIF-1 also suppressed Wnt signaling pathway,
resulting in the tumor growth and lung metastasis in vivo in
OSmousemodels [50]. These results indicate thatWIF-1 can
be a therapeutic agent against OS metastasis. However, the
function of Wnt antagonists including WIF-1 is still unclear
and further investigations are needed.
Notch signaling regulates development of many tissues
and cell types through diverse eﬀects on cell fate decision,
stem cell renewal, diﬀerentiation, survival, and proliferation
[87]. Notch signaling is one of several evolutionarily con-
served signaling pathways in the development of multicel-
lular organisms. Its temporal-spatial expression eﬀects can
specify diverse cellular events, including proliferation, differ-
entiation, apoptosis, and stem cell maintenance. In mam-
mals, there are four Notch receptors: Notch1-4, and elev-
en ligands [88]. The first targets of Notch are two ba-
sic helix-loop-helix transcriptional repressor families: the
Hairy/enhancer-of-split (Hes) and the Hes with YRWPmotif
families [89]. Notch has been considered as a promoter of
invasion in OS. The Notch receptor 1, 2, and Hes1 genes
induced by Notch increase in highly metastatic OS. The
Hes1 gene was inversely associated with the survival rate in
human OS [52–55]. The OS cell invasion was reduced by an
inhibition of the Notch signaling pathway whereas the cell
proliferation was not blocked in a preclinical setting. The
Notch-inhibited cells were less able to induce lungmetastases
in an orthotopic mouse than the negative controls. However,
the mechanism in the inhibition of the Notch pathway and
the downregulation of invasion resulted from Hes1 remains
not clear [53, 55].
Src is a nonreceptor tyrosine kinase and encoded by the
c-Src as a protooncogene. Src kinase activity is regulated by
several receptor tyrosine kinases (RTKs) such as epidermal
growth factor (EGF) RTK, PDGF-RTK, and integrin recep-
tors [90–92]. Src family kinases are critical in the metastatic
dissemination, such as cell proliferation, adhesion, invasion,
survival, and angiogenesis. Either overexpression or activa-
tion of c-Src has been shown to occur in cancer development
[49]. Src, involved in tumor metastasis widely, could be a
novel therapeutic target in OS metastasis. Dasatinib, known
as a Src kinase inhibitor, suppresses Bcr-Abl tyrosine kinase.
The eﬀect and safety of dasatinib have been established as
therapeutic agent for imatinib-resistant chronic myeloge-
nous leukemia in early-phase clinical trials. Also, several
studies have shown that the dasatinib acts against Bcr-Abl-
positive leukemic cell lines as well as other malignancies.
The c-Src-mediated signaling pathways, related to tumor
proliferation, adhesion, or migration, have been shown in
various malignancies such as prostate cancer, lung cancer,
and sarcoma [93–95]. In preclinical studies, dasatinib sup-
pressed tumor migration and invasion with inhibition of the
Src kinase activity and its downstream signaling in OS cell
lines in vitro [48, 96]. On the other hand, dasatinib had no
eﬀect on pulmonary metastases in vivo [48]. At present, the
other specific Src kinase inhibitor, called saracatinib, is under
investigation in phase II clinical trial of OS lung metastases
(clinicaltrials.gov/ct2/show/NCT00752206).
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4. Apoptosis Resistance and OS Progression
Apoptosis is involved in cell survival in cancer metastasis
through the all stages via two pathways. The first one is reg-
ulated by a death-receptor-bound to Fas or tumor-necrosis
factor (TNF) family member, death-inducing signaling com-
plex, and caspase-8. The second one is associated with p53,
Bcl2 family member, cytochrome-c, and caspase-9. When
caspase-8 or -9 is activated, caspases of the downstream can
be cleaved inducing cell death. Fas and its ligand (FasL)
belong to the TNF death receptor superfamily and reg-
ulate tumorigenesis in a variety of primary malignancies
and metastases [97–99]. Fas/FasL complex, constitutively
expressed in lung tissue, enhances the Fas-apoptosis pathway
and leads to cell death [100, 101]. Fas receptor has been well
known as a death receptor mediated apoptosis in a variety
of tumor cells. Recent studies have revealed that Fas is also
proapoptotic related to tumor proliferation, diﬀerentiation,
and migration [102–104]. Thus, apoptosis resistance is
crucial for establishment of tumor metastasis; it is implicated
in treatment resistance with cancer metastasis [105]. Fas
expression is often decreased in OS lung metastasis, whereas
it is highly expressed in the primary tumors [100, 101, 106].
Furthermore, Fas-negative expressions correlate with tumor
development and poor prognosis [100, 101, 107–109]. Inhi-
bition of Fas signaling and/or the loss of FasL can develop
the proliferation of Fas-positive OS cells in the lungs and can
promote the growth of lung metastases in OS models in vivo
[107].
Interleukin- (IL-) 12 increased the expressions of Fas
receptor in OS lung metastasis through stimulation of the
Fas promoter activity. In turn, the metastatic cells acquired
the susceptibility to FasL in relation to Fas-induced apoptosis
in the lung microenvironment [110]. In vivo, combination
therapy of IL-12 with ifosfamide induces FasL expression,
increasing the therapeutic eﬃcacy via the Fas/FasL pathway
[111]. Muramyl tripeptide phosphatidyl ethanolamine
(MTP-PE) induces IL-12 production in OS patients through
activation of macrophages [1, 112]. MTP-PE also up-
regulates Fas expression when exogenous IL-12 is admin-
istered to the patients [106]. The combination of MTP-
PE with ifosfamide induces IL-12 and FasL, respectively,
consequently the clinical outcome of the treated patients
can be improved through the activation of tumor apoptosis
[106]. These results suggest that Fas death receptor pathway
may enhance the eﬃcacy of chemotherapy in OS.
IL-18, which is an interferon-γ-inducing factor [113],
aﬀects an antitumor eﬀect via the activation of natural killer
(NK) cells or cytotoxic T cells [113, 114], inhibition of
angiogenesis [115] and induction of FasL on Fas-positive
tumor cells [116]. IL-18 has been shown to inhibit metastasis
in OS cells through the activation of T-cells and NK-cells
and the induction of the FasL expression [117]. In addition,
the combination of ifosfamide with IL-18 suppresses the
development of OS lung metastasis [118]. Taken together,
Fas death receptor pathway is essential in the establishment
of OS lung metastasis, and it may be a novel therapeutic
target. However, the molecular mechanism of the loss of Fas-
mediated apoptosis in OS metastases is unknown.
5. Survival in the Blood Circulation:
Anoikis Resistance
Cancer metastases require the anoikis-resisted cells to sur-
vive in the circulation. Anoikis, Greek for “homelessness,”
regulates cell homeostasis in tissues. Normal epithelial cells
become apoptotic when exposed to anchorage-independent
environments [119, 120]. In turn, once tumor cells have en-
tered into the bloodstream to disseminate distantly, the cell-
cell adhesions or ECM attachments are lost, which results
in the specific apoptosis called anoikis [121]. Therefore,
metastatic cells need to acquire the resistance to anoikis to
survive during dissemination and colonization of secondary
distant sites in the circulation.
Acquisition of anoikis resistance has been described in
nonepithelial malignancies such as OS [122]. Many studies
demonstrated the survival mechanism of cancer cells in the
evasion of anoikis with various means such as Src/PI3K/Akt
pathway, focal adhesion kinase, or Bcl-2 [123, 124]. Several
studies have shown that β4 integrin expression is involved in
cancer progression [125–127]. The β4 integrin expression is
also implicated in the survival of OS cells in the circulation,
because knockdown of β4 integrin suppressed the cell-
proliferation under anchorage-independent sites in OS cells
[128]. In addition, the knockdown of β4 integrin in a mouse
model inhibited lung metastases, and β4 integrin-ezrin
interaction appears to be essential for β4 integrin expression.
However, the relation between ezrin and β4 integrin is still
unknown [128]. Cell-cell adhesions can activate integrin
signaling in anchorage-independent conditions and integrin
expression patterns may contribute to the resistance to
anoikis [129].
Switch from αVβ5 to αVβ6 integrin may suppress anoikis
in squamous cell carcinoma cells through the activation of
PI3K/Akt signaling pathway [130]. The PI3K/Akt pathway,
which depends on Src kinase activation, is important for
human OS cells to avoid anoikis [47]. Src has another role
related to anoikis resistance with caveolin-1 in OS cells.
Caveolin-1 is the major protein component of caveolae
[131], which regulates several intracellular signaling path-
ways [132]. Caveolin-1 is highly expressed in osteoblasts
[133] and its overexpression in OS cells inhibited anchorage-
independent growth, invasion, and migration by blocking c-
Src and c-Met tyrosine kinases in vitro [134]. In addition,
Caveolin-1 overexpression suppressed the OS metastasis in
vivo [134].
6. Arrest and Extravasation:
Final Step of Cell Migration
The mechanism of migration arrest of metastatic cells is
controversial. Metastatic tumor cells are generally thought to
be trapped in the microcirculation because their size is larger
than that of normal cells [135]. When the tumor cells in the
bloodstream are trapped, microembolisms are structured,
and the interaction with the local microenvironment begins
consequently. Interestingly, cancer cells have the tendency
to prefer a specific target organ in metastasis processes:
Over 80% of all metastases in OS occur in the lungs [136].
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This result suggests that circulating tumor cells can select
their optimal sites to survive and grow via interactions with
distinct molecules expressed on the endothelial cells in the
distant organs [16]. In the circulation, cell colonization in
the distant organs is mediated through the secretion of
chemokines and proteinases, involved in extravasations [15,
16]. Recently, chemokines are regarded as important factors
to control a site specificity of cancer metastasis including OS-
lung relation [137–140]. C-X-C-motif chemokine receptor
4 (CXCR4) and its ligand C-X-C-motif chemokine ligand
12 (CXCL12) have been shown to regulate an organ-specific
metastasis by the formation of chemotactic gradients in
several cancer [141–143]. Binding of CXCR4 to CXCL12
allows adhesion and extravasation of OS cells in pulmonary
metastasis [138, 139, 144, 145]. These results suggest that
abundant expressions of CXCL12 in the lungmay be involved
in the high frequency of pulmonary metastases in OS.
Highly CXCR4 expressions in OS-patient samples adversely
correlated to event-free, overall, and metastasis-free survival
[138]. These data suggest that CXCR4 could be useful as a
prognostic factor in OS metastasis.
CXCR3, another chemokine receptor, has been identified
in a variety of malignancies including OS [138, 146–148].
Its ligands, CXCL9, 10, and 11, are expressed in lungs. The
inhibition of CXCR3 chemokine pathway down regulates
the growth of OS lung metastasis. Recent study has demon-
strated that CXCR3 inhibitor decreased the proliferation,
survival and invasion of the tumor cells in an animal model
of OS lung metastasis. In other words, the interaction be-
tween CXCR3 and its ligands can directly enhance the
invasion, survival, and proliferation of tumor cells in the
metastatic organ. This result suggests that targeting CXCR3
can specifically inhibit OS lung metastasis [144].
7. Adhesion Step in theMetastatic Process
Establishment at a distant organ requires that the metastatic
cell connects to its new environment and re-establishes
cell-cell adhesions. Ezrin is a membrane-cytoskeleton linker
protein that acts as membrane organizers and linkers be-
tween plasma membrane and cytoskeleton controlling cell-
microenvironment and cell-cell interactions [149]. In addi-
tion, ezrin associates with several signaling transductions,
such as Rho and PI3K/Akt pathways [150, 151]. Recently,
high level expression of ezrin protein is correlated tometasta-
sis in several cancers [152–154] as well as OS [155, 156]. High
expression of ezrin is associated with pulmonary metastasis
in animal models [155, 157], and with poor outcome in
pediatric OS patients [155]. Phosphorylated ezrin was shown
to express at just early phase in lung metastasis [155] whereas
it was dynamically expressed at both the early and late time
point [156].
Sorafenib is a multipotent drug, and several molecular
targets of sorafenib such as Raf kinases are implicated in
OS development [158, 159]. Recent preclinical study has
reported that sorafenib suppressed the development of lung
metastases via downregulation of ezrin-activated mitogen-
activated protein kinase (MAPK)/Akt signaling [160]. In
addition, sorafenib could induce apoptosis through a
decrease of expression of the antiapoptotic Bcl-2 family
[160]. These data suggest sorafenib may be a novel potential
therapeutic option in patients with OS metastasis.
8. Main Signaling Pathways Involved in
Proliferation of Metastatic OS
OS pathogenesis is clearly related with bone growth during
adolescence, suggesting a potential relationship with higher
expression of hormone levels [161, 162]. Thus, several stud-
ies have suggested that molecular alterations in the growth
hormone (GH)/insulin-like growth factor I (IGF-I) signaling
pathways could lead to OS development in vitro and in vivo
[163, 164]. OS cells show both IGF-I and IGF-I receptor
expression and highly response to IGF-I in vitro [164]. Serum
IGF-I levels in mice with hypophysectomy are significantly
downregulated, which is decreasing tumor growth and
development of metastasis [165].
A phase I trial in patients with metastatic and/or recur-
rent OS was performed with somatostatin analog (OncoLar)
to reduce serum IGF-I [166]. In this trial, OncoLar treatment
in 21 OS patients resulted in a 46% decrease in serum IGF-
I levels without toxicity. In a preclinical study conducted on
dogs with naturally occurring OS, OncoLar [167] reduced
serum IGF-I levels were by approximately 43% without
toxicity. However, no diﬀerence in primary tumor necrosis,
apoptosis, or survival was observed in dogs treated with a
combination of OncoLar and chemotherapy in comparison
with just chemotherapy. These observations indicate that the
extent or duration of serum IGF-I suppression induced by
OncoLar was not enough to improve a clinical outcome.
IGF-I receptor (IGF-IR) axis is also implicated in OS devel-
opment; inhibition of IGF-IR could inhibit tumor growth,
activate apoptosis and up-regulate the chemosensitivity and
radiosensitivity in OS cells [168, 169].
Recently, human monoclonal antibodies targeting the
IGF-IR were tested in both preclinical and clinical studies.
Inhibition of IGF-IR with some monoclonal antibodies
enhances the antitumor eﬀects in several OS xenograft mod-
els [170, 171]. More recently, a clinical study has demon-
strated that high IGF-IR expression is a poor prognostic
factor for OS patients leading to OS development and
metastasis [172]. Thus, IGF-IR targeting therapy can be a
novel strategy for the treatment of OS associated with
metastasis.
9. Dormancy
Unfortunately, tumor metastasis occasionally occurs for pa-
tients with malignancies a long time after the success of
primary therapy [173, 174]. This latency period is generally
the result of tumor dormancy, which is frequently asymp-
tomatic and clinically undetectable for months or years until
relapse. Once tumor cells are settled in a secondary site,
they can grow, die by apoptosis, or remain dormant. Two
ways of tumor dormancy have been described, (i) tumor
mass dormancy (dormant micrometastases) and (ii) cellular
dormancy [174–176]. In dormant micrometastases, tumor
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Figure 2: Tumor metastasis dormancy is associated with the risk of recurrence of OS and late development of lung metastases. Tumor
dormancy is thought to consist of tumor mass dormancy (dormant micrometastases) and cellular dormancy. In tumor mass dormancy
(dormant micrometastases), tumor cells generally divide but not in cellular dormancy. The tumor growth is strictly limited by the lack of
blood supply or immune system. Dormant state of micrometastases is involved in angiogenic switch and/or the adaptive immune system.
Dormancy therapy could contribute to improve the treatment of patients with cancer.
cells generally divide but the growth is limited. Cellular
dormancy (dormant single tumor cell) can occur when
tumor cells enter in a quiescence state and do not divide
any more. Tumor cells in dormancy are usually resistant to
conventional drug because current treatments target cells in
division. However, the mechanisms allowing dormant tumor
cells to survive to conventional chemotherapies and then
resume the tumor outgrowth remain unknown.
Dormant micrometastases are thought to be present
under a balance between cell proliferation and apoptosis
[176, 177]. Dormant state of micrometastases is involved in
lack of nutrition and oxygen from vasculature in relation
to angiogenic switch and/or the adaptive immune system
[178–182]. Endothelial cells in the microenvironment can
enhance dormant tumor cells via cell-to-cell interactions and
induction of angiogenesis [180]. The ECM also plays an
important role in activation of dormant cells. When tumor
cells fail to adhere to the ECM, they may enter in dormancy.
It has been postulated that micrometastases fail to properly
connect to the ECM and survive in the dormant state because
they are deprived of growth factors and angiogenic signaling.
Adhesion to the ECM could induce tumor cells to switch a
dormancy state to a proliferation state via integrin signaling
[181]. On the other hand, both tumor cells and host stromal
cells modulate the microenvironment such as ECM and
vascular walls. Those mechanisms may regulate the mainte-
nance in dormancy or the activation metastatic growth for a
single tumor cell or micrometastases respectively (Figure 2)
[17, 181].
In vivo molecular mechanisms of a variety of cancers
including OS in dormant state have been assessed with
genome transcriptional analysis [181]. This study suggests
that antiangiogenic proteins such as angiomotin, which has
been shown to suppress tumor growth and keep dormancy of
tumor metastases [179], are upregulated during dormancy.
Thus, the tumor proliferation and invasion are inhibited
under preangiogenic state. Tumor cells in proliferation state
also increased the key cancer pathways such as EGF receptor-
1, IGF-IR, and PI3K. The mechanism of regulating tumor
dormancy is unknown in OS. However, if it is possible to
induce and/or keep in a dormant state or to induce cell death
in residual dormant cells by targeting their survival and drug
resistance mechanisms, the treatment for the patients with
OS may be further improved.
10. Conclusion
OS associated with metastases still have poor clinical out-
come, and conventional therapies are not fully eﬀective. In
addition, clinical output of novel available chemotherapeutic
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approaches is still unclear. Recent studies have disclosed
new insights into the molecular mechanisms of metastasis as
above mentioned. However, much more unknown questions
remain; determinant factors of selective colonization in dif-
ferent organs, the mechanisms of tumor dormancy, and the
mechanisms of metastasis suppressors, and so forth. Thus,
future research critically needs to be directed towards identi-
fying the molecular alterations in OS microenvironments.
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